P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL

• T. Hughes,
• J. E. Cortes,
• D. Réa,
• M. J. Mauro,
• A. Hochhaus,
• D.-W. Kim,
• K. Sasaki,
• F. Lang,
• M. C. Heinrich,
• M. Breccia,
• M. Deininger,
• Y.-T. Goh,
• J. J. Janssen,
• M. Talpaz,
• V. Gómez García de Soria,
• P. le Coutre,
• S. Kapoor,
• S. Cacciatore,
• F. Polydoros,
• N. Agrawal,
• F.-X. Mahon

Affiliations

T. Hughes

1 SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia

J. E. Cortes

2 Georgia Cancer Center, Augusta, United States of America

D. Réa

3 Hôpital Saint-Louis, Paris, France

M. J. Mauro

4 Memorial Sloan Kettering Cancer Center, New York, United States of America

A. Hochhaus

5 Universitätsklinikum Jena, Jena, Germany

D.-W. Kim

6 Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea

K. Sasaki

7 The University of Texas MD Anderson Cancer Center, Houston, United States of America

F. Lang

8 Goethe University Hospital, Frankfurt, Germany

M. C. Heinrich

9 Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, United States of America

M. Breccia

10 Policlinico Umberto I-Sapienza University, Rome, Italy

M. Deininger

11 Versiti Blood Research Institute, Milwaukee, United States of America

Y.-T. Goh

12 Singapore General Hospital, Bukit Merah, Singapore

J. J. Janssen

13 Amersterdam University Medical Centers, Amersterdam, Netherlands

M. Talpaz

14 University of Michigan Rogel Cancer Center, Ann Arbor, United States of America

V. Gómez García de Soria

15 Hospital Universitario La Princesa, Madrid, Spain

P. le Coutre

16 Charité - Universitätsmedizin Berlin, Berlin, Germany

S. Kapoor

17 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Cacciatore

18 Novartis Pharma AG, Basel, Switzerland

F. Polydoros

18 Novartis Pharma AG, Basel, Switzerland

N. Agrawal

18 Novartis Pharma AG, Basel, Switzerland

F.-X. Mahon

19 Institut Bergonié, Bordeaux, France